Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we are pleased to provide hereunder the proceedings of 40th AGM of the Company held on Tuesday, September 30, 2025 through Video ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gennex Laboratories held its 40th AGM on September 30, 2025, via video conferencing, from 12:30 PM to 1:11 PM, with 48 members attending. Chairman and Managing Director Mr. Arihant Baid presided over the meeting and gave an overview of FY 2024-25 operations, financial performance, and pharma sector outlook. Five ordinary resolutions were transacted, including adoption of audited standalone and consolidated financial statements for FY ending March 31, 2025, re-appointment of Mr. Arihant Baid as Director (retiring by rotation), regularization of Mr. Sandeep Kumar Daga as Non-Executive Director, appointment of Mr. Md. Tausif Shamim as Secretarial Auditor, and ratification of Cost Auditor remuneration. Two independent directors (Mr. Dilip Raj Singhvi and Mr. Amudala Sreeramulu Nageswar Rao) were absent due to unavoidable reasons. The consolidated voting results from remote e-voting and e-voting at the AGM are awaited and will be submitted to the stock exchanges within prescribed timelines.
This is a routine regulatory disclosure of AGM proceedings with all resolutions being ordinary business items. No material strategic decisions, fund-raising, or major changes were announced. Voting results are still pending, which could provide incremental insight once released, but the meeting itself has no immediate price impact.